Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03710915 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

Start date: August 11, 2018
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.

NCT ID: NCT03687125 Active, not recruiting - Clinical trials for Multiple Myeloma in Relapse

Tinostamustine Conditioning and Autologous Stem Cell

TITANIUM1
Start date: September 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1 The primary objectives of Phase 1 of this study are to: Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen. Identify the recommended Phase 2 dose (RP2D) of tinostamustine for use in the Phase 2 portion of the study. The secondary objective of Phase 1 of this study is to: Investigate the pharmacokinetics (PK) of tinostamustine.

NCT ID: NCT03674463 Active, not recruiting - Clinical trials for Refractory or Relapsed Multiple Myeloma

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Start date: July 26, 2018
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of LCAR-B4822M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).

NCT ID: NCT03672253 Active, not recruiting - Multiple Myeloma Clinical Trials

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Start date: July 26, 2018
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.

NCT ID: NCT03493737 Active, not recruiting - Multiple Myeloma Clinical Trials

Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma

ADHOMY
Start date: April 10, 2018
Phase:
Study type: Observational

Bortezomib needs repetitive visits at hospital for injections. Hospital-at-Home (HaH) might be an attractive and suitable alternative in this situation. This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France.

NCT ID: NCT03412565 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Start date: April 26, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.

NCT ID: NCT03357952 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Start date: November 16, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone (Part 2); and to compare progression-free survival (PFS) in participants treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone (Part 3).

NCT ID: NCT03327597 Active, not recruiting - Clinical trials for Monoclonal Gammopathy of Undetermined Significance

Iceland Screens, Treats or Prevents Multiple Myeloma

iStopMM
Start date: September 1, 2016
Phase: N/A
Study type: Interventional

This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.

NCT ID: NCT03318861 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

Start date: October 31, 2017
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of KITE-585, an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA. Patients will be given a 3 day course of chemotherapy followed by a single infusion of KITE-585.

NCT ID: NCT03277105 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Start date: October 27, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).